Quiz: Infection, Tumor imaging, and Therapy Review Test (3/3) (employee training


Infection, Tumor imaging, and Therapy Review Test (3/3)Online version Multiple choice by Joshua Liberty 1 Yttrium (90Y)-Ibritumomab tiuxetan 1rst step in therapy is? a Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills b Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab c Give 4 mCi/kg of Y-90 non-labeled rphx d Give 0.4 mCi/kg of Y-90 non-labeled rphx 2 Yttrium (90Y)-Ibritumomab tiuxetan 2nd step in therapy is? a Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills b Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab c Give 4 mCi/kg of Y-90 non-labeled rphx d Give 0.4 mCi/kg of Y-90 non-labeled rphx 3 Iobenguane I-131 Dosimetric (not therapy) dose is? a Patients weighing greater than 25 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.9 mCi/kg b Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 1 mCi/kg c Patients weighing greater than 50 kg: 3 or 4 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg d Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg 4 Iobenguane I-131 patient prep includes: patients should increase fluid intake to at least 2 L a day starting at least 1 day before and continuing for 1 week after each iobengaune I-131 dose _______? a To minimize irradiation to the bladder b To reduce bladder in FOV c To prevent vomiting d To increase the TNT ratio 5 Iobengaune I-131 Therapy dose is? a Patients weighing > than 92.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg b Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg c Patients weighing > than 62.5 kg: 600 mCi, Patients weighing 62.5 kg or <: 5 mCi/kg d Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 4 mCi/kg 6 Fluciclovine F-18 dose is? a 5 mCi b 15-20 mCi c 6 mCi d 10 mCi 7 Fluciclovine F-18 MOL is? a Compartmental near prostate glandular tissue b Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors c Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells d Passive diffusion into prostate cancer cells 8 Lutetium Lu-177 dotatate MOL or mechanism of action is? a Passive diffusion through cell membrane of normal/malignant B lymphocytes b Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors c Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells d Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized 9 Fluciclovine F-18 patient prep includes? a Avoid any significant exercise for at least one day prior to PET imaging b No food or water 8 hours prior to injection c Block thyroid using inorganic iodine d Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection 10 Lutetium Lu-177 Dotatate recommended dose is? a 100 mCi every 8 weeks for a total of 4 doses b 200 mCi every 8 weeks for a total of 4 doses c 200 mCi every 4 weeks for a total of 4 doses d 200 mCi every 2 weeks for a total of 4 doses 11 Lutetium Lu-177 Dotatate patient prep includes? a Avoid any significant exercise for at least one day prior to PET imaging b No food or water 4 hours prior to injection c Block thyroid using inorganic iodine d Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection 12 Lutetium Lu-177 Dotatate causes? a Excessive bone irradiation b Known cardiac damage c Myelosuppression d Lung radiation pneumonitis if shunting occurs 13 Lu-177 Dotatate critical organ is? a Liver b Spleen c Kidneys d Bladder 14 Cu-64 dotatate dose is ? a 4 mCi b 15-20 mCi c 6 mCi d 10 mCi e 10-15 mCi 15 Piflufolastat F-18 dose is? a 4 mCi b 9 mCi (range 8-10 mCi) c 6 mCi d 0.4 mCi/kg e 10-15 mCi 16 The recommended start time for image acquisition is ___ minutes after Piflufolastat injection. Starting image acquisition more than ____ minutes after injection may adversely impact imaging performance. a 60; 90 b 30; 60 c 15; 30 d 90; 120 e 120;180 17 Cu-64 Tp is? a 6.6 days b 64 hours c 64 minutes d 12.7 hours e 12.7 days 18 Regarding Cu-64 dotatate patient prep, for patients on long-acting somatostatin analogs, a wash-out period of ____ is recommended prior to imaging. a 14 days; 2 days b 28 days; 2 days c 28 hours; 2 hours d 14 days; 7 days e 28 days; 4 days 19 Piflufolastat F-18 MOL or mechanism of action is? a Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA b Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors c Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells d Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized 20 A patient is having Y90 Resin Microspheres therapy. He has >50% liver involvement, dose =? a 3 GBq b 5 GBq c 2.5 GBq d 2 GBq 21 Lymphoscintigraphy may use a CO-57 flood source; this is called a? a Flow image b Transmission scan c Emission scan d Blood pool scan 22 Ideal matrix size for a PET/CT scan would be ___ or higher a 512x512 b 32x32 c 128x128 d 64x64 23 A technologist draws an ROI too small on a lesion which takes up FDG. The result will be ? a Higher average SUV b Lower average SUV c No effect on SUV d No effect on SUV if AC was used 24 Melanoma tumor thickness is called the? a SUV b Clark index c Breslow index d Arelle index e Ritter index 25 A patient is on dextrose; it should be discontinued ______ before FDG injection. a 8-10 hours b 1-2 hours c 3-4 hours d 6-8 hours e 10-12 hours

1

Yttrium (90Y)-Ibritumomab tiuxetan 1rst step in therapy is?

a

Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills

b

Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab

c

Give 4 mCi/kg of Y-90 non-labeled rphx

d

Give 0.4 mCi/kg of Y-90 non-labeled rphx

2

Yttrium (90Y)-Ibritumomab tiuxetan 2nd step in therapy is?

a

Give IV rituximab, which is cold antibody; this blocks CD20 sites in peripheral circulation and RES uptake; pretreat with acetaminophen and diphenhydramine for fever/chills

b

Wait 7-9 days, then give 2nd infusion IV cold rituximab followed by therapeutic dose 0.3 or 0.4 mCi/kg (<32 mCi) Y-90 labeled Ibritumomab

c

Give 4 mCi/kg of Y-90 non-labeled rphx

d

Give 0.4 mCi/kg of Y-90 non-labeled rphx

3

Iobenguane I-131 Dosimetric (not therapy) dose is?

a

Patients weighing greater than 25 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.9 mCi/kg

b

Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 1 mCi/kg

c

Patients weighing greater than 50 kg: 3 or 4 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg

d

Patients weighing greater than 50 kg: 5 or 6 mCi, Patients weighing 50 kg or less: 0.1 mCi/kg

4

Iobenguane I-131 patient prep includes: patients should increase fluid intake to at least 2 L a day starting at least 1 day before and continuing for 1 week after each iobengaune I-131 dose _______?

a

To minimize irradiation to the bladder

b

To reduce bladder in FOV

c

To prevent vomiting

d

To increase the TNT ratio

5

Iobengaune I-131 Therapy dose is?

a

Patients weighing > than 92.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg

b

Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 8 mCi/kg

c

Patients weighing > than 62.5 kg: 600 mCi, Patients weighing 62.5 kg or <: 5 mCi/kg

d

Patients weighing > than 62.5 kg: 500 mCi, Patients weighing 62.5 kg or <: 4 mCi/kg

6

Fluciclovine F-18 dose is?

a

5 mCi

b

15-20 mCi

c

6 mCi

d

10 mCi

7

Fluciclovine F-18 MOL is?

a

Compartmental near prostate glandular tissue

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors

c

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

d

Passive diffusion into prostate cancer cells

8

Lutetium Lu-177 dotatate MOL or mechanism of action is?

a

Passive diffusion through cell membrane of normal/malignant B lymphocytes

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors

c

Synthetic amino acid transported across mammalian cell membranes by amino acid transproters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

d

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized

9

Fluciclovine F-18 patient prep includes?

a

Avoid any significant exercise for at least one day prior to PET imaging

b

No food or water 8 hours prior to injection

c

Block thyroid using inorganic iodine

d

Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection

10

Lutetium Lu-177 Dotatate recommended dose is?

a

100 mCi every 8 weeks for a total of 4 doses

b

200 mCi every 8 weeks for a total of 4 doses

c

200 mCi every 4 weeks for a total of 4 doses

d

200 mCi every 2 weeks for a total of 4 doses

11

Lutetium Lu-177 Dotatate patient prep includes?

a

Avoid any significant exercise for at least one day prior to PET imaging

b

No food or water 4 hours prior to injection

c

Block thyroid using inorganic iodine

d

Administer IV amino acid solution containing L-lysine and L-arginine 30 minutes before administering dose. Continue the infusion during, and for at least 3 hours after dose infusion. This is done for renal protection

12

Lutetium Lu-177 Dotatate causes?

a

Excessive bone irradiation

b

Known cardiac damage

c

Myelosuppression

d

Lung radiation pneumonitis if shunting occurs

a

Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA

b

Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in neuroendocrine tumors

c

Synthetic amino acid transported across mammalian cell membranes by amino acid transporters, such as LAT-1 and ASCT2, which are upregulated in prostate cancer cells

d

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized

20

A patient is having Y90 Resin Microspheres therapy. He has >50% liver involvement, dose =?

a

3 GBq

b

5 GBq

c

2.5 GBq

d

2 GBq

21

Lymphoscintigraphy may use a CO-57 flood source; this is called a?

a

Flow image

b

Transmission scan

c

Emission scan

d

Blood pool scan

22

Ideal matrix size for a PET/CT scan would be ___ or higher

a

512x512

b

32x32

c

128x128

d

64x64

23

A technologist draws an ROI too small on a lesion which takes up FDG. The result will be ?

a

Higher average SUV

b

Lower average SUV

c

No effect on SUV

d

No effect on SUV if AC was used

24

Melanoma tumor thickness is called the?

a

SUV

b

Clark index

c

Breslow index

d

Arelle index

e

Ritter index

25

A patient is on dextrose; it should be discontinued ______ before FDG injection.

a

8-10 hours

b

1-2 hours

c

3-4 hours

d

6-8 hours

e

10-12 hours

Infection, Tumor imaging, and Therapy Review Test (3/3)

Quiz

Download the paper version to play

Created by

Top 10 results

Top Games

Quiz

UPS 5 Seeing Habits Quiz

Quiz

Photosynthesis vs Cellular Respiration - Practice Quiz

Quiz

Tissues - Practice Quiz

Quiz

Spanish Alphabet Listening

Quiz

Practice Quiz - Punnett Square, Variation, and Mutations